136 related articles for article (PubMed ID: 29485532)
1. STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-α.
Machiraju D; Moll I; Gebhardt C; Sucker A; Buder-Bakhaya K; Schadendorf D; Hassel JC
Melanoma Res; 2018 Jun; 28(3):204-210. PubMed ID: 29485532
[TBL] [Abstract][Full Text] [Related]
2. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
Lesinski GB; Valentino D; Hade EM; Jones S; Magro C; Chaudhury AR; Walker MJ; Carson WE
Cancer Immunol Immunother; 2005 Sep; 54(9):815-25. PubMed ID: 15668815
[TBL] [Abstract][Full Text] [Related]
3. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
[TBL] [Abstract][Full Text] [Related]
4. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.
Wang W; Edington HD; Rao UN; Jukic DM; Land SR; Ferrone S; Kirkwood JM
Clin Cancer Res; 2007 Mar; 13(5):1523-31. PubMed ID: 17332298
[TBL] [Abstract][Full Text] [Related]
5. STAT5 contributes to interferon resistance of melanoma cells.
Wellbrock C; Weisser C; Hassel JC; Fischer P; Becker J; Vetter CS; Behrmann I; Kortylewski M; Heinrich PC; Schartl M
Curr Biol; 2005 Sep; 15(18):1629-39. PubMed ID: 16169484
[TBL] [Abstract][Full Text] [Related]
6. Effects of high-dose IFNalpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3, and IL-17.
Wang W; Edington HD; Rao UN; Jukic DM; Radfar A; Wang H; Kirkwood JM
Clin Cancer Res; 2008 Dec; 14(24):8314-20. PubMed ID: 19088050
[TBL] [Abstract][Full Text] [Related]
7. STAT5 contributes to antiapoptosis in melanoma.
Hassel JC; Winnemöller D; Schartl M; Wellbrock C
Melanoma Res; 2008 Dec; 18(6):378-85. PubMed ID: 19011510
[TBL] [Abstract][Full Text] [Related]
8. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Meyer S; Wild PJ; Vogt T; Bataille F; Ehret C; Gantner S; Landthaler M; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
Exp Dermatol; 2010 Aug; 19(8):e251-7. PubMed ID: 20500769
[TBL] [Abstract][Full Text] [Related]
9. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions.
Kirkwood JM; Farkas DL; Chakraborty A; Dyer KF; Tweardy DJ; Abernethy JL; Edington HD; Donnelly SS; Becker D
Mol Med; 1999 Jan; 5(1):11-20. PubMed ID: 10072444
[TBL] [Abstract][Full Text] [Related]
10. Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment.
Smith AP; Kirkwood JM; Edington HD; Jukic DM; Farkas DL; Becker D
Mol Imaging; 2003 Jan; 2(1):65-73. PubMed ID: 12926238
[TBL] [Abstract][Full Text] [Related]
11. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
12. Interferon-alpha treatment may negatively influence disease progression in melanoma patients by hyperactivation of STAT3 protein.
Humpoliková-Adámková L; Kovařík J; Dušek L; Lauerová L; Boudný V; Fait V; Fojtová M; Krejčí E; Kovařík A
Eur J Cancer; 2009 May; 45(7):1315-1323. PubMed ID: 19232485
[TBL] [Abstract][Full Text] [Related]
13. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy.
Wang W; Edington HD; Rao UN; Jukic DM; Wang H; Shipe-Spotloe JM; Kirkwood JM
J Invest Dermatol; 2008 Aug; 128(8):1997-2002. PubMed ID: 18305569
[TBL] [Abstract][Full Text] [Related]
14. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
15. Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.
Sim GC; Wu S; Jin L; Hwu P; Radvanyi LG
Oncotarget; 2016 Jun; 7(24):36074-36091. PubMed ID: 27153543
[TBL] [Abstract][Full Text] [Related]
16. STAT5 phosphorylation in malignant melanoma is important for survival and is mediated through SRC and JAK1 kinases.
Mirmohammadsadegh A; Hassan M; Bardenheuer W; Marini A; Gustrau A; Nambiar S; Tannapfel A; Bojar H; Ruzicka T; Hengge UR
J Invest Dermatol; 2006 Oct; 126(10):2272-80. PubMed ID: 16741510
[TBL] [Abstract][Full Text] [Related]
17. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma.
Hammock L; Cohen C; Carlson G; Murray D; Ross JS; Sheehan C; Nazir TM; Carlson JA
J Cutan Pathol; 2006 Sep; 33(9):599-607. PubMed ID: 16965333
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal roles of STAT3 and STAT5 in nasal polyposis.
Wang XQ; Hu GH; Kou W; Shen Y; Kang HY; Hong SL
Am J Otolaryngol; 2012; 33(6):741-52. PubMed ID: 22959364
[TBL] [Abstract][Full Text] [Related]
20. Constitutive STAT5 activation correlates with better survival in cervical cancer patients treated with radiation therapy.
Chen HH; Chou CY; Wu YH; Hsueh WT; Hsu CH; Guo HR; Lee WY; Su WC
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):658-66. PubMed ID: 21300446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
